Effect of Fenofibrate on Sleep Apnea Syndrome

A 1-month, Randomized, Double-blind, Placebo-controlled Study of Fenofibrate 145 mg Tablet in Patients With Sleep Apnea Syndrome

Objectives: to investigate for the potential effect of fenofibrate on symptoms and biological changes associated with sleep apnea syndrome.

Inclusion Criteria:

• Having previous diagnosis of sleep apnea not treated with Continuous Positive Airway Pressure (CPAP) or presenting clinical symptoms of sleep apnea
• Overweight or obese, with BMI >= 25 kg/m² and < 40 kg/m².
• Known moderate hypertriglyceridemia, with fasting Triglycerides level >= 2.0 and < 6.0 mmol/L within 3 months before the inclusion.

Exclusion Criteria:

• indication for immediate CPAP
• other known endocrine disease, except treated and adequately controlled hypothyroidism
• renal failure or plasma creatinine level >130 µmol/L
• current chronic liver disease or ALanine Amino Transferase (ALT)> 2 times the upper normal limit (UNL)
• symptomatic gallbladder disease
• known muscular disease or creatine phosphokinase (CK) > 3 times UNL.